Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes

Carl V. Asche, C. Mcadam-Marx, L. Shane-Mcwhorter, X. Sheng, C. A. Plauschinat

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Objective: To quantify adverse events (AEs) associated with the use of metformin (MET), sulphonylureas (SUs) and thiazolidinediones (TZDs) in a usual care setting, and to assess the relationship of AEs to treatment patterns and glycaemic response in patients with type 2 diabetes. Research design and methods: An electronic medical record database was used to identify patients with type 2 diabetes age ≥18years from 1996 to 2005. Patients naïve to oral antidiabetic therapy were followed for 395days postinitiation of MET, SU or TZD treatment. AEs related to study drugs were evaluated during the follow-up period. Baseline and follow-up A1C levels were compared by drug regimen. Associations between the change in A1C, drug regimen changes and AEs were evaluated. Results: A total of 14512 patients (mean age 60.8 years, 52.9% female) were identified. During the follow-up period, 12.7% of patients experienced an AE (8.6% MET, 15.9% SU and 19.8% TZD patients). SU and TZD patients were more likely to experience an AE than MET (p < 0.001) patients. AEs did not significantly influence A1C outcomes, although MET and SU patients experiencing an AE were more likely to add-on therapy (odds ratio (OR) = 1.34 and OR = 1.37, respectively; p<0.05) than those without an AE. MET patients with AEs were more likely to switch therapy (OR = 1.91; p < 0.05) than those without an AE. Conclusions: The occurrence of AEs did not significantly impact glycaemic response to therapy. However, AEs may lead to greater treatment switches for patients receiving MET and add-on therapy for MET-treated and SU-treated patients.

Original languageEnglish (US)
Pages (from-to)638-645
Number of pages8
JournalDiabetes, Obesity and Metabolism
Issue number8
StatePublished - Aug 2008
Externally publishedYes


  • Adverse events
  • Electronic medical records
  • Glycemic control
  • Outcomes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes'. Together they form a unique fingerprint.

Cite this